G
Gwen L. Nichols
Publications - 5
Citations - 67
Gwen L. Nichols is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 54 citations.
Papers
More filters
Journal ArticleDOI
The advisory dean program: a personalized approach to academic and career advising for medical students.
William Macaulay,Lisa A. Mellman,Donald O. Quest,Gwen L. Nichols,Joseph Haddad,Peter J. Puchner +5 more
TL;DR: The AD Program has become a key element for enhancing the students' professional development throughout their student training, focusing on topics including, but not limited to, career counseling, professionalism, humanism, and wellness resources.
Journal ArticleDOI
Anti-spike T-cell and Antibody Responses to SARS-CoV-2 mRNA Vaccines in Patients with Hematologic Malignancies
Lee M. Greenberger,Larry Saltzman,Lore Gruenbaum,Jun Xu,Sneha T Reddy,Jonathon W. Senefeld,Patrick W. Johnson,Paul Fields,Catherine Sanders,Louis J. DeGennaro,Gwen L. Nichols +10 more
TL;DR: Vaccinated patients with B cell malignancies with a poor response to SARS-CoV-2 vaccines may remain vulnerable to COVID-19 infections, and anti-spike antibody levels were depressed by B cell-directed therapies.
Journal ArticleDOI
ITCC-101/APAL2020D: A Randomized Phase 3 Trial of Fludarabine/Cytarabine/Gemtuzumab Ozogamycin with or without Venetoclax in Children with Relapsed Acute Myeloid Leukemia
Sae Ishimaru,GE Gueguen,Seth E. Karol,Francisco J. Bautista Sirvent,Valeria Ceolin,Bianca F. Goemans,Marlous Bakker,Laura Di Laurenzio,Jennifer Lukin,Harm van Tinteren,Gauri Sunkersett,Maika Onishi,K. Unnebrink,Dirk Reinhardt,Gwen L. Nichols,E. Anders Kolb,C. Michel Zwaan +16 more
TL;DR: Venetoclax is a small molecule inhibitor of B-cell lymphoma-2 (BCL-2) that restores programmed cell death in cancer cells, and is approved for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) in combination with hypomethylating agents or low-dose cytarabine, who are ineligible for intensive chemotherapy as mentioned in this paper .
Journal ArticleDOI
Feasibility and Preliminary Findings of a Novel, Patient-Centric Registry Model to Address Real-World Care Questions for Patients with Hematologic Malignancies
S. Cornew,Anthony B Cardillo,Louis J. DeGennaro,Paul Fields,Lore Gruenbaum,Hana Littleford,Richard L Martin,Gwen L. Nichols,A. Nottke,C. O'Brien,Sneha T Reddy,Rhonda Rosenbaum,Larry Saltzman,Catherine Sanders,Jun Xu,Lee M. Greenberger +15 more
TL;DR: The Leukemia & Lymphoma Society National Registry (LLS-Registry) as mentioned in this paper is a platform that coordinates large-scale patient advocacy-based recruitment and research objectives with high quality data collection and insights generation.
Journal ArticleDOI
Danger ahead: COVID-19 infections after vaccination
TL;DR: A harbinger of trouble had already appeared based on the remarkable 34% risk of death among adult patients with blood cancer infected with COVID-19 observed shortly after the pandemic began but before vaccines became available in December 2020.